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ABSTRACT 1 
Despite decades of research and major innovations in technology, cardiovascular 2 
disease remains the leading cause of death globally. Our understanding of major 3 
cardiovascular events and their prevention is centred around the atherosclerotic 4 
plaque and the processes that ultimately lead to acute plaque rupture. Recent 5 
advances in hybrid imaging technology allow the combination of high spatial 6 
resolution and anatomical detail with molecular assessments of disease activity. This 7 
provides the ability to identify vulnerable plaque characteristics and differentiate 8 
active and quiescent disease, with the potential to improve patient risk stratification. 9 
Combined positron emission tomography and computed tomography is the 10 
prototypical non-invasive hybrid imaging technique for coronary artery plaque 11 
assessment. In this review we discuss the current state of play in the field of hybrid 12 
coronary atherosclerosis imaging.  13 
14 
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KEYWORDS 15 
Vulnerable plaque 16 
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 23 
ABBREVIATIONS 24 
CMR  Cardiac magnetic resonance 25 
CT  Computed tomography 26 
CTCA  Computed tomography coronary angiography 27 
FFR  Fractional flow reserve 28 
FFRCT Computed tomography coronary angiography-derived fractional flow 29 
reserve 30 
MRCA Magnetic resonance coronary angiography 31 
PET  Positron emission tomography 32 
33 
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INTRODUCTION 34 
Cardiovascular disease is the leading cause of death globally, despite advances in 35 
risk stratification, diagnostic tools and preventative therapies (1). Consequently, 36 
there remains major interest in refining our current methods of diagnosis and risk 37 
stratification to better individualise preventative therapies. Myocardial infarction is 38 
most commonly caused by rupture of atherosclerotic plaque. Plaques that are prone 39 
to rupture have certain common characteristics that together define the vulnerable 40 
plaque. Vulnerable plaques have played an integral role in our understanding of 41 
atherosclerosis and cardiovascular disease, with extensive research conducted to 42 
better characterise and identify these lesions (2). However, appreciation of the fact 43 
that the majority of vulnerable plaques ruptures are clinically silent has led to a 44 
paradigm shift in atherosclerotic plaque imaging; focus has shifted from the level of 45 
the individual plaque to the patient (3), and from invasive to non-invasive imaging 46 
modalities. This change has coincided with advances in non-invasive imaging 47 
techniques which now facilitate comprehensive assessments of plaque 48 
characteristics and disease activity across the coronary vasculature. Hybrid 49 
cardiovascular imaging is at the frontier of clinical research in this field, although it 50 
has yet to become adopted for routine clinical use. 51 
 52 
HYBRID IMAGING:  RATIONALE AND CONCEPTS 53 
The pathophysiology of atherosclerosis and the vulnerable plaque is well-described 54 
(2). There are hallmarks characteristics of high-risk plaque that have been identified 55 
on histology, invasive intracoronary imaging and computed tomography coronary 56 
angiography (CTCA) which serve as specific targets for hybrid coronary imaging. 57 
The prototypical thin-cap fibroatheroma features inflammation (predominantly 58 
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macrophage infiltration), a large lipid-rich necrotic core, a thin fibrous cap (<65 µm), 59 
superficial microcalcification and plaque haemorrhage. Notably, these findings are 60 
independent of stenosis severity; myocardial infarction is often due to plaque rupture 61 
in non-obstructive lesions (4, 5).  As our ability to image these plaques has improved 62 
it has become clear that the majority of these lesions appear to either heal or rupture 63 
sub-clinically with only very few leading to myocardial infarction. In the landmark 64 
PROSPECT trial (4), 596 thin-cap fibroatheromas were identified on virtual-histology 65 
intravascular ultrasound (IVUS) in a cohort of 697 patients with acute coronary 66 
syndrome. After 3 years’ follow-up, only 31 myocardial infarctions, cardiac arrests or 67 
cardiac deaths occurred. Of these, 14 were related to the original culprit lesion. The 68 
recent Lipid Rich Plaque study demonstrated that the lipid core burden index on 69 
near-infrared spectroscopy IVUS predicted both culprit and non-culprit major adverse 70 
cardiovascular events at 24 months (6). The value of invasive assessments of 71 
plaque morphology and plaque-directed therapies has therefore been questioned. 72 
Vulnerable plaque assessment appears to be of greater value at the level of the 73 
patient, using non-invasive imaging to interrogate the entire coronary vasculature. 74 
Those subjects in whom adverse plaque characteristics are identified are at 75 
increased risk of future events, although the originally identified lesion may not itself 76 
result in a clinical event. As such, total atherosclerotic burden has yet to be 77 
superceded for prognostic purposes by any plaque-level imaging (3). 78 
 79 
Hybrid imaging techniques combine two different modalities, taking advantage of 80 
their individual strengths to provide a comprehensive dataset. A modality with high 81 
temporal and spatial resolution is required to provide anatomical detail and 82 
assessments of soft tissue composition. For the coronary arteries, the most common 83 
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of these is CTCA, although cardiovascular magnetic resonance (CMR) can also be 84 
utilised. For hybrid coronary plaque assessment, this dataset is most commonly 85 
fused with positron emission tomography (PET). This allows interrogation of plaque 86 
biology and potentially any disease process but requires appropriately targeted 87 
radiotracers. The ability of hybrid PET-CT and PET-MR to provide this breadth of 88 
information about anatomy, plaque composition and disease activity make them 89 
exciting techniques with which to study coronary atherosclerosis. 90 
 91 
HYBRID IMAGING: PLAQUE CHARACTERISTICS 92 
Non-invasive imaging of vulnerable plaque morphology has been extensively studied 93 
with CT and MR as described below. 94 
 95 
Computed tomography coronary angiography 96 
CTCA has been at the forefront of coronary plaque characterisation for many years, 97 
with studies demonstrating close correlation between CTCA and intravascular 98 
imaging findings of thin-cap fibroatheromas (7, 8). There are several classic CTCA 99 
features of vulnerable plaque: low-attenuation (<30 Hounsfield Units), positive 100 
remodelling (commonly defined as a remodelling index >1.1), spotty calcification and 101 
the napkin-ring sign (low-attenuation plaque core with a rim of higher attenuation). 102 
Early data from Motoyama et al described the increased prevalence of low 103 
attenuation plaque (79% vs 9%), positive remodelling (87% vs 12%) and spotty 104 
calcification (63% vs 21%) in culprit lesions compared to stable lesions (9). Further 105 
prospective data demonstrated an increased rate of acute coronary syndromes in 106 
patients with high-risk plaque (16.3% vs 1.4% at mean follow-up of 3.9 ± 2.4 years, 107 
hazard ratio [HR] 8.24 (95% confidence interval [CI] 5.26 – 12.96)) (10). There now 108 
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exists a large body of non-randomised evidence supporting these findings (5, 9-12). 109 
Recent analyses from the two largest randomised trials of CTCA in symptomatic 110 
patients with suspected stable coronary artery – the Prospective Multicenter Imaging 111 
Study for Evaluation of Chest Pain (PROMISE) and Scottish Computed Tomography 112 
of the Heart (SCOT-HEART) trials – have added further weight to the prognostic 113 
power of CTCA assessments of vulnerable plaque. In PROMISE, 676 (15%) patients 114 
had high-risk plaque, conferring a greater risk of major adverse events after 115 
adjustment for significant stenoses and atherosclerotic cardiovascular disease risk 116 
score (HR 1.72, 95% confidence interval [CI] 1.89 – 3.93) (13). Of note, this 117 
incremental prognostic power was seen only in patients with non-obstructive 118 
disease. In SCOT-HEART, adverse plaque features, present in 608 (34%) patients 119 
(40% of patients with non-obstructive plaque and 75% in those with obstructive 120 
plaque), conferred a 3-fold higher risk of coronary heart disease death or nonfatal 121 
myocardial infarction (HR 3.01, 95% CI 1.61 – 5.63), an effect that was most 122 
pronounced during short-term follow-up. The high prevalence of adverse plaque 123 
features demonstrates the relatively low positive predictive value of these findings. 124 
The prognostic power of adverse plaque features was not independent of coronary 125 
artery calcium score, highlighting the importance of total atherosclerotic disease 126 
burden. Additionally, approximately half of patients with subsequent adverse events 127 
did not have obstructive coronary artery disease, while (14). It is important to note 128 
the clinical context of these trials, as vulnerable plaque features may perhaps be 129 
more relevant in the acute setting (15) due to the dynamic nature of plaque biology 130 
and the increased use of long-term preventative therapies .    131 
 132 
Cardiovascular magnetic resonance 133 
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CMR has become an imaging modality of major interest in recent years as a result of 134 
improvements in scanner technology and software. CMR offers a multiparametric 135 
approach to cardiovascular imaging, providing unparalleled soft tissue 136 
characterisation that is of particular value in the myocardium, alongside information 137 
regarding anatomy, function, perfusion and viability. CMR is also able to characterise 138 
coronary atherosclerosis, utilising non-contrast T1-weighted (black blood) imaging to 139 
detect methaemoglobin found in acute intraplaque haemorrhage or intraluminal 140 
thrombosis.  High-intensity coronary plaques correlate well with CTCA findings of low 141 
attenuation and positive remodelling, demonstrate increased rates of in-situ 142 
thrombus, and have been shown to reduce in intensity after statin therapy (16-20). 143 
Meanwhile, novel targeted contrast agents have been developed, such as THI0567-144 
targeted liposomal-gadolinium. This agent binds with high affinity to integrin α4β1, a 145 
key integrin involved in recruiting inflammatory cells to atherosclerotic plaques, and 146 
is able to detect vulnerable aortic plaque in an animal model (21). However, as a 147 
result of the inferior spatial resolution compared to CTCA, magnetic resonance 148 
coronary angiography (MRCA) is largely restricted to the proximal and mid-vessel 149 
coronary segments. Sequences such as the Coronary Atherosclerosis T1-weighted 150 
Characterization with integrated anatomical reference (CATCH) (22) have been 151 
developed to overcome some of these limitations but remain exploratory at this point 152 
in time. The majority of clinical research and histological validation has therefore 153 
focused on larger, stationary vessels such as the carotid artery. Longer scan times in 154 
comparison to CTCA, cost and accessibility are other potential barriers to wider 155 
uptake of CMR for imaging of coronary atherosclerosis. 156 
 157 
HYBRID IMAGING: DISEASE ACTIVITY 158 
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Molecular nuclear imaging techniques utilise targeted probes bound to radioactive 159 
isotopes. An understanding of plaque biology and the various components of 160 
vulnerable plaque are critical to determine suitable targets for molecular imaging. 161 
PET has been studied for many years, primarily in other specialties such as 162 
oncology. Coronary PET imaging has previously been limited due to poor spatial 163 
resolution, partial volume effects and cardiac motion. However, with improvements in 164 
scanners and the development of advanced motion correction and co-registration 165 
techniques, many of these limitations have been overcome. There is now major 166 
research interest in coronary PET imaging for the assessment of disease activity 167 
within atherosclerotic plaques.  This interest had led to the advent of bespoke tracers 168 
targeting specific aspects of plaque biology to complement the use of more 169 
established radiotracers that have been re-purposed from other fields. 170 
 171 
Positron emission tomography: 18F-fluorodeoxyglucose 172 
18F-fluorodeoxyglucose (18F-FDG) PET has been used widely in oncology for many 173 
years and was first utilised to image atherosclerosis in the carotid artery in 2002 (23). 174 
As a glucose analogue, it is metabolised and accumulates intracellularly in tissues 175 
with high metabolic activity via the glucose transporter protein system. 18F-FDG has 176 
therefore been used as a non-specific marker of vascular inflammation in the aorta, 177 
carotids and femoral arteries. 18F-FDG uptake has been shown to correlate with the 178 
presence of atherosclerosis, features of plaque vulnerability, biomarkers of 179 
inflammation (in particular macrophage burden) and clinical cardiovascular risk (24-180 
26).   181 
 182 
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Although the 18F-FDG PET is excellent for myocardial viability assessment due to 183 
avid uptake in cardiomyocytes, coronary artery uptake is often obscured by the 184 
adjacent myocardial signal. This is the main limitation of 18F-FDG for coronary 185 
atherosclerosis imaging, even despite dietary restrictions prior to scanning (27-29). 186 
18F-FDG may still prove of value in detecting plaque inflammation in the aorta and 187 
carotid arteries; large prospective outcome studies are awaited.  188 
 189 
Positron emission tomography: 18F-sodium fluoride 190 
Given 18F-FDG’s lack of specificity, other radiotracers have been explored. 18F-191 
sodium fluoride (18F-NaF) has been used as a bone tracer and for the detection of 192 
bony metastases for many decades but has now found a potential application in 193 
hybrid cardiac imaging. The ligand for 18F-NaF is hydroxyapatite, a key component 194 
of early bone and vascular calcification. It preferentially binds to micro- rather than 195 
macrocalcification due to the higher exposed surface area of hydroxyapatite (30). 196 
Microcalcification is thought to be an early healing response to cell necrosis and 197 
inflammation that precedes the development of larger, macroscopic deposits of 198 
calcium which can stabilise plaque. Microcalcification within a thin fibrous cap may 199 
also increase local stress and destabilize the plaque, thereby increasing the chance 200 
of rupture (31). Coronary microcalcification is therefore a key component of 201 
vulnerable plaque and a biologically plausible target for imaging, with 18F-NaF 202 
providing different information to the more established, stable macrocalcification 203 
identified on CT.  204 
 205 
18F-NaF PET-CT was noted to identify aortic plaque in 2010 (32). Subsequent data 206 
has shown that increased 18F-NaF activity can be identified in the coronary arteries, 207 
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localising to individual plaques and demonstrating excellent inter-observer 208 
repeatability (33). This improved ability to detect discrete coronary artery uptake 209 
compared to 18F-FDG appears to be due to low 18F-NaF uptake in the adjacent 210 
myocardium and very high affinity of the tracer for microcalcification (30, 34) Again, 211 
18F-NaF appears to be providing different information to the presence of calcium on 212 
CT;  in one study, almost a half of patients with a calcium score >1000 Agatston 213 
units did not have any coronary 18F-NaF uptake (33). In keeping with the hypothesis 214 
that 18F-NaF uptake is associated with vulnerable plaque, several clinical studies 215 
have demonstrated uptake to be associated with culprit and high-risk coronary 216 
plaque as defined by invasive angiography, intravascular ultrasound and CTCA. In 217 
the first report, increased 18F-fluoride uptake was observed at the site of the culprit 218 
coronary plaque in 37 of the 40 patients with recent myocardial infarction (29), a 219 
finding supported by two subsequent smaller studies (35, 36).  220 
 221 
Recent technological advances have greatly improved the image quality of coronary 222 
18F-NaF PET-CT imaging. These techniques have focused on optimizing image 223 
reconstruction and correcting for cardiac, respiratory and gross patient motion, with 224 
the important advantage that they can be applied retrospectively to PET datasets 225 
(37-39). Newer data have also demonstrated the feasibility of fusing PET data with 226 
previously acquired CTCA, expanding the potential practical application of this form 227 
of imaging (40). 18F-NaF PET-MR is also feasible with lower doses of ionising 228 
radiation, but currently cannot provide the spatial resolution of CTCA for coronary 229 
artery imaging (41). 230 
 231 
Positron emission tomography: other radiotracers 232 
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Multiple alternative radiotracers, each with a specific target, have been studied for 233 
use in atherosclerosis (Table 1) (42). 68Ga-DOTATATE, which targets the 234 
somatostatin receptor subtype 2 (SSTR2) on the surface of activated 235 
proinflammatory M1 macrophages, has recently been investigated for coronary 236 
atherosclerosis imaging. The Vascular Inflammation imaging using Somatostatin 237 
receptor positron emissION tomography (VISION) study utilised RNA sequencing, 238 
autoradiology, histology and PET-CT in patients with stable and unstable 239 
cardiovascular disease. The investigators elegantly demonstrated exclusive 240 
expression of SSTR2 in M1 macrophages within atherosclerotic plaque, a strong 241 
correlation between SSTR2 expression and 68Ga-DOTATATE activity, and 242 
improved discrimination of culprit and high-risk plaque in both the coronary and 243 
carotid arteries compared to 18F-FDG (43). Further studies are keenly anticipated. 244 
Other examples of alternative radiotracers include 11C-PK11195, which is a specific 245 
ligand of the translocator protein that is highly expressed on activated phagocytes, 246 
and the chemokine receptor CXCR4, which is upregulated in unstable plaque and 247 
colocalizes with CD68 inflammatory cells. 11C-PK11195 is able to image intraplaque 248 
haemorrhage in recently symptomatic carotid plaques (44) as well as active disease 249 
in large-vessel vasculitis, while CXCR4 has recently shown promise for the 250 
distinguising culprit and non-culprit coronary plaques in ST-elevation myocardial 251 
infarction (45). 252 
 253 
HYBRID IMAGING: PHYSIOLOGY 254 
In addition to measurements of plaque composition and disease activity, PET/CT 255 
also allows for functional assessments of atherosclerotic lesions, whether using 256 
myocardial perfusion studies or non-invasive fraction flow reserve (FFR). This is of 257 
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interest as recent data have suggested that vulnerable plaque characteristics are 258 
associated with haemodynamically significant lesions, and that integrating luminal 259 
stenosis, adverse plaque characteristics and adverse haemodynamic characteristics 260 
(comprised of CT-derived FFR (CT-FFR), delta CT-FFR across the vessel, wall 261 
shear stress and axial plaque stress) provides better identification of culprit lesions 262 
than each individual parameter (46). Functional coronary assessments may 263 
therefore act as both surrogates of adverse plaque features, as well as an additional 264 
modality to add incremental prognostic information. 265 
 266 
With invasive FFR now routinely used for decision making in interventional 267 
cardiology, interest has grown in the potential for CT-FFR to enhance the role of 268 
CTCA as a gatekeeper to invasive angiography. Although CT-FFR does not image 269 
vulnerable plaque directly, several studies have demonstrated that CTCA 270 
assessments of plaque composition improve discrimination of ischaemic lesions as 271 
defined by an invasive FFR ≤ 0.80 or by decreased quantitative myocardial blood 272 
flow (47-51). The number of adverse plaque features appear to increase as stenosis 273 
severity increase, but the presence of high-risk plaque also remains an independent 274 
predictor of ischaemia regardless of stenosis severity, particularly positive 275 
remodelling (47, 48, 51). The mechanisms for these findings are not clear but reflect 276 
the complex relationship between coronary atherosclerosis and ischemia. Positive 277 
remodelling and the lipid-rich necrotic core of the vulnerable plaque may predispose 278 
to local endothelial dysfunction and altered shear stress, thus altering impairing 279 
arterial vasomotor function. This hypothesis is supported by a recent exploratory 280 
study in which high-risk plaque characteristics were more strongly related to invasive 281 
pressure measurements during hyperaemia than during rest (52). The adaptive 282 
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arterial remodelling response to the progression of atheroma – the Glagov 283 
phenomenon – may also reach its limit with a certain volume of plaque, at which 284 
point luminal encroachment, obstruction to flow and ischaemia may rapidly progress 285 
(53). 286 
 287 
PET provides the gold standard non-invasive assessment of myocardial perfusion. 288 
Unlike FFR, PET is able to provide a quantitative assessment of absolute 289 
hyperaemic blood flow and myocardial blood flow reserve, thus integrating the 290 
combined effect of epicardial coronary arterial atherosclerosis as well as 291 
microvascular disease. The Prospective Comparison of Cardiac PET/CT, SPECT/CT 292 
Perfusion Imaging and CT Coronary Angiography With Invasive Coronary 293 
Angiography (PACIFIC) study demonstrated PET to be superior to CTCA and single-294 
photon emission computed tomography (SPECT) for the diagnosis of ischaemia 295 
(based on invasive FFR) (54). Although this study showed only limited additional 296 
diagnostic value with hybrid imaging, a recent meta-analysis confirmed incremental 297 
diagnostic performance with hybrid anatomy/perfusion imaging compared to CTCA 298 
(55). Additionally, several retrospective studies consistently described an 299 
incremental prognostic value of combining myocardial perfusion imaging and CTCA 300 
(56, 57). Further data is now needed to investigate the association between adverse 301 
plaque features and myocardial perfusion on PET, to assess whether the latter might 302 
also provide a surrogate for unstable coronary plaque phenotypes. 303 
 304 
The future of non-invasive coronary anatomy/physiology imaging is therefore 305 
extremely promising; there is great appeal in deriving a hybrid dataset assessing 306 
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coronary anatomy, plaque morphology, plaque burden and coronary flow at both a 307 
lesion and vessel level. Randomized clinical trials will be highly anticipated.  308 
 309 
CURRENT LIMITATIONS 310 
Although the appeal of hybrid imaging is clear, there remain some limitations. Most 311 
crucially, until recently there has been a lack of randomised data demonstrating the 312 
ability of these imaging techniques to change outcomes. We now have this data 313 
supporting the use of CTCA, but there is a major need for similar data demonstrating 314 
the benefits of hybrid non-invasive ischaemia testing. Furthermore, access to 315 
scanners and integration of these imaging techniques into clinical workflows in 316 
imaging departments must be considered. Costs is also an issue, particularly with 317 
regards to the production of bespoke radiotracers for nuclear imaging. Consequently, 318 
which test to use in which patients in what setting must be carefully considered, 319 
taking into account all of these factors. This is in addition to other clinical factors that 320 
may influence the choice of test, such as patient age, likelihood of calcific disease, 321 
ability to achieve adequate heart rate control, comorbidities and acceptable radiation 322 
dose. 323 
 324 
CASE 1 325 
A 57-year-old man with type 2 diabetes mellitus presented with a non-ST elevation 326 
myocardial infarction (NSTEMI) and underwent percutaneous coronary intervention 327 
with two drug-eluting stents to the proximal right coronary artery (RCA) and posterior 328 
left ventricular artery (PLV). Six months later, he re-presented with another NSTEMI 329 
despite appropriate preventative therapies. Invasive coronary angiography 330 
demonstrated severe in-stent restenosis in the proximal stent and a further severe 331 
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de novo mid-RCA (Figure 1A). Optical coherence tomography demonstrated plaque 332 
rupture with red thrombus in the mid-vessel lesion and aggressive neointimal 333 
hyperplasia in the proximal lesion (Figure 1B-C). Two drug-eluting stents were 334 
implanted with a good angiographic result (Figure 1D). The left system, particularly 335 
the left anterior descending artery (LAD), had diffuse plaque without obstructive 336 
disease (Figure 1E). As part of a research study, the patient underwent 18F-NaF 337 
PET-CT six weeks later. This demonstrated three discrete regions of focal uptake in 338 
the proximal, mid and distal RCA (arrows). Although the mid-RCA lesion was the 339 
culprit, the highest uptake was in the proximal restenotic lesion. In contrast to the 340 
RCA, the diffusely diseased LAD had non-obstructive calcific plaque without high-341 
risk features on CTCA and did not demonstrate any 18F-NaF uptake (Figure 1F). 342 
 343 
CASE 2 344 
A patient was referred three weeks after an episode of chest pain with a late 345 
presentation myocardial infarction. He was not revascularized due to established 346 
infarction. Six months post-infarct, he underwent 18F-NaF PET-MR. Whole-heart, 3-347 
dimensional, contrast-enhanced coronary MR angiography using a respiratory-348 
navigated, electrocardiographically triggered, inversion-recovery fast spoiled 349 
gradient-echo sequence demonstrated a severe culprit plaque in the proximal LAD 350 
(Figure 1A). Extensive near-transmural infarction in this territory was seen on late 351 
gadolinium enhancement (Figure 1B). Focal 18F-NaF uptake was noted in the culprit 352 
lesion (Figure 1C-D, white arrowheads) as well as in the aorta and mitral annulus 353 
(black arrows). Adapted from Robson et al (41). 354 
 355 
CONCLUSIONS 356 
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The field of cardiovascular atherosclerosis imaging is burgeoning, with increasing 357 
availability and uptake of CT and CMR in particular. Hybrid imaging platforms 358 
combine these modalities with PET, which together provide detailed information 359 
about coronary anatomy, flow, plaque morphology and disease activity, potentially 360 
expanding our pathophysiological understanding of atherosclerosis and improving 361 
risk stratification. Further studies are now required to investigate the clinical utility of 362 
this approach and determine whether hybrid imaging of the vulnerable plaque can 363 
improve patient outcomes. 364 
365 
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FIGURE LEGENDS 
 
Figure 1 
Invasive angiography (A, D, E), optical coherence tomography (B, C) and positron 
emission tomography-computed tomography (F, G) for Case 1. Descriptions 
provided in case vignette.  
 
Figure 2 
Cardiac magnetic resonance for Case 2. Descriptions provided in case vignette.  
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Table 1 Positron emission tomography radiotracers targeting vulnerable plaque  
 
Target Ligand Radiotracer 
 
Current applications in atherosclerosis 
 
Macrophage 
activation 
Glucose transporter protein 
system. Conversion to 18F-
FDG-6-phosphate and 
intracellular accumulation 
18F-FDG  Prospective in vivo studies in extracardiac 
atherosclerosis. Correlation with 
atherosclerosis and cardiovascular risk. 
Myocardial signal spill-over limits coronary 
artery assessment (35, 37). 
 
 Somatostatin receptor 
subtype 2 
68Ga-DOTATATE  Prospective in vivo studies in cardiac and 
extracardiac atherosclerosis. Correlation with 
culprit coronary lesions and high-risk features 
on CTCA (52). 
 
 Translocator protein 18-kDa 11C-PK11195 Prospective in vivo study in carotid 
atherosclerosis (67). Short half-life and 
variable metabolism. 
 
 Choline kinase 
phosphorylated to 
phosphatidylcholine 
18F-FCH  Retrospective in vivo study demonstrating 
correlation with large vessel atherosclerosis 
and an inverse relationship with calcification 
(68). 
 
Apoptosis Phosphatidylserine Annexin V Prospective in vivo pilot data in carotid 
atherosclerosis (69). 
 
Hypoxia Reduction to amine 
derivative in low oxygen 
environment 
18F-FMISO  Prospective in vivo pilot data in carotid 
atherosclerosis (70). 
 
 Reduction to amine 
derivative in low O2 
environment 
18F-HX4 Prospective in vivo pilot data in carotid 
atherosclerosis (71). 
Microcalcification Hydroxyapatite 18F-NaF Prospective in vivo studies in coronary and 
extracardiac atherosclerosis. Correlation with 
culprit coronary lesions and high-risk features 
on CTCA  (37, 41, 44, 72). 
 
Angiogenesis αVβ3 & αVβ5 integrin 18F-Fluciclatide  Prospective in vivo pilot data in the aorta 
(73). 
 
 
αVβ3 integrin 18F-RGD-K5  Ex vivo study in carotid atherosclerosis (74).  
 
Thrombus 
 
 
Glycoprotein IIb/IIIa platelet 
receptor 
18F-GP1 Prospective in vivo pilot data in arterial 
thromboembolic disease (75). 
18F-FDG: 18-fluorodeoxyglucose, CTCA: computed tomography coronary angiography, 18F-FCH: 18F-fluorocholine, 
18F-FMISO: 18F-fluoromisonidazole, 18F-HX4: 18F-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-
yl)propan-1-ol, 18F-NaF: 18F-sodium fluoride, 18F-RGD-K5: arginine-glycine-aspartate-K5. 
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